Testosterone Replacement Therapy and Longevity

TRT can improve sexual symptoms in men with confirmed testosterone deficiency. It has not been shown to extend life, and safe use depends on repeat testing, fertility planning, and follow-up.

9 min read

May 12, 2026

Sexual WellnessHormone OptimizationTestosteroneBody Composition

On this page0% read

What TRT Is, and How It Differs From Performance Dosing
The Routes: Injections, Gels, Pellets, and Fertility-Preserving Options
What Men Notice on TRT
What TRT Means for Heart, Bone, and Lifespan
Confirming Testosterone Deficiency: Testing and Retesting
Monitoring a TRT Plan
TRT and Fertility
Where TRT Fits in a Longevity Plan
References

Start Here

Testosterone replacement therapy (TRT) is an evidence-based treatment for men with symptoms and consistently low morning testosterone levels. It can improve sexual function and may modestly improve mood in this group. Evidence does not show that TRT prevents cardiovascular disease, diabetes, fractures, or early death. Using testosterone to “optimize” a normal level is not a guideline-supported indication and has not been tested for longevity.

What a responsible TRT plan covers

The diagnosis

Symptoms must be considered with repeat morning testosterone tests and an evaluation for reversible or underlying causes.

The treatment goal

Define which symptoms should improve and understand that raising a laboratory value does not prove a longevity benefit.

The safety plan

Follow testosterone level, hematocrit, blood pressure, prostate context, fertility goals, and sleep-apnea risk.

TRT discussions often begin with fatigue, lower desire, erectile changes, mood, or reduced strength. Those symptoms are common and can have many causes. A careful evaluation determines whether testosterone deficiency is present and whether treatment is likely to address the problem.

What TRT Is, and How It Differs From Performance Dosing

Testosterone is a steroid hormone made primarily in the testicles. It supports sexual function, muscle and bone, red-blood-cell production, and other body systems. TRT replaces testosterone when a clinical deficiency causes symptoms or signs.

TRT aims to restore levels to a normal physiologic range under medical supervision. Performance-enhancing use typically involves higher doses or combinations intended to produce levels beyond the normal range. Both involve a steroid hormone, but the dose, goal, evidence, and risk context differ.

Clinical trials and guidelines focus on men with symptoms and confirmed low levels. The Endocrine Society recommends against prescribing testosterone for age-related decline alone ¹. Evidence is insufficient to say that raising a normal testosterone level improves healthspan or lifespan. If a clinic offers “optimization,” ask what diagnosis and outcome support the prescription.

The Routes: Injections, Gels, Pellets, and Fertility-Preserving Options

Format: Injection
What it usually means: Testosterone is injected on a regular schedule.
Trade-offs to weigh: Levels can vary between doses. Injections may raise hematocrit more than gels and require comfort with needles.

Format: FDA-approved gel
What it usually means: Testosterone is applied to the skin every day.
Trade-offs to weigh: Absorption varies, and the medicine can transfer to a partner or child through skin contact. Compounded creams are a separate category.

Format: Pellets
What it usually means: Small pellets are placed under the skin every few months.
Trade-offs to weigh: Placement requires a minor procedure, and the dose cannot be reduced quickly after insertion.

Format: Oral
What it usually means: Newer testosterone capsules are taken by mouth.
Trade-offs to weigh: Instructions vary by product. Oral therapy still requires testosterone, hematocrit, and blood-pressure monitoring.

Format: Fertility-preserving approaches
What it usually means: Medicines such as hCG (human chorionic gonadotropin) or clomiphene stimulate the body's own pathway.
Trade-offs to weigh: These are separate from TRT and may be considered when fertility matters. Evidence, approval status, and suitability depend on the drug and diagnosis [2].

Format	What it usually means	Trade-offs to weigh
Injection	Testosterone is injected on a regular schedule.	Levels can vary between doses. Injections may raise hematocrit more than gels and require comfort with needles.
FDA-approved gel	Testosterone is applied to the skin every day.	Absorption varies, and the medicine can transfer to a partner or child through skin contact. Compounded creams are a separate category.
Pellets	Small pellets are placed under the skin every few months.	Placement requires a minor procedure, and the dose cannot be reduced quickly after insertion.
Oral	Newer testosterone capsules are taken by mouth.	Instructions vary by product. Oral therapy still requires testosterone, hematocrit, and blood-pressure monitoring.
Fertility-preserving approaches	Medicines such as hCG (human chorionic gonadotropin) or clomiphene stimulate the body's own pathway.	These are separate from TRT and may be considered when fertility matters. Evidence, approval status, and suitability depend on the drug and diagnosis [2].

Formulation choice comes after the diagnosis. The dose is adjusted using symptoms, a properly timed testosterone level, adverse effects, and hematocrit ¹. Cost and daily burden also matter. If near-term fertility is a goal, discuss it before the first dose because standard TRT suppresses sperm production.

What Men Notice on TRT

In the Testosterone Trials, older men with low testosterone had modest improvements in sexual activity, desire, and erectile function ³. Sexual symptoms have some of the best treatment evidence, although erectile dysfunction can still require evaluation for vascular, medication, or psychological causes.

Mood and depressive symptoms improved slightly in the same program ³. Its primary vitality measure did not improve, so energy should not be promised as a reliable result. Fatigue that persists on TRT deserves evaluation for sleep, mood, anemia, thyroid disease, medication effects, and other causes.

Define the treatment goal before starting and record a baseline. At follow-up, review the symptoms that supported the diagnosis rather than judging treatment by the testosterone result alone. A higher value without meaningful improvement should prompt reconsideration of the dose, diagnosis, or plan.

What TRT Means for Heart, Bone, and Lifespan

TRT can improve a measurement without improving the clinical outcome that matters. In imaging studies, testosterone increased spine bone density and estimated strength ⁵. In a larger fracture analysis, 3.5% of men receiving testosterone had a clinical fracture compared with 2.5% receiving placebo ⁶. TRT should not be used as a fracture-prevention treatment.

Outcome: Major cardiovascular events
What the trials found: TRAVERSE found testosterone noninferior to placebo in men with symptoms, low testosterone, and existing or elevated cardiovascular risk [4].
Dimension: Healthspan
What not to overread: Noninferiority supports cardiovascular safety in the studied population. It does not show cardiovascular benefit.

Outcome: Other cardiovascular findings
What the trials found: Atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often with testosterone [4].
Dimension: Healthspan
What not to overread: These were secondary findings and still belong in risk counseling.

Outcome: Bone
What the trials found: Bone density and estimated strength improved [5], but clinical fractures were more frequent with testosterone [6].
Dimension: Healthspan
What not to overread: Do not assume that a better scan means fewer fractures.

Outcome: Blood sugar
What the trials found: Testosterone did not prevent progression from prediabetes to diabetes [7].
Dimension: Healthspan
What not to overread: TRT is not a diabetes-prevention or metabolic treatment.

Outcome: Sexual function and energy
What the trials found: Sexual function improved modestly, while the primary vitality measure did not [3].
Dimension: Wellspan
What not to overread: Set expectations by outcome instead of promising a general boost.

Outcome: Living longer
What the trials found: No randomized trial has shown that TRT extends life. Low natural levels are associated with mortality in observational data [8].
Dimension: Lifespan
What not to overread: An association does not show that treatment changes lifespan.

Outcome	What the trials found	Dimension	What not to overread
Major cardiovascular events	TRAVERSE found testosterone noninferior to placebo in men with symptoms, low testosterone, and existing or elevated cardiovascular risk [4].	Healthspan	Noninferiority supports cardiovascular safety in the studied population. It does not show cardiovascular benefit.
Other cardiovascular findings	Atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often with testosterone [4].	Healthspan	These were secondary findings and still belong in risk counseling.
Bone	Bone density and estimated strength improved [5], but clinical fractures were more frequent with testosterone [6].	Healthspan	Do not assume that a better scan means fewer fractures.
Blood sugar	Testosterone did not prevent progression from prediabetes to diabetes [7].	Healthspan	TRT is not a diabetes-prevention or metabolic treatment.
Sexual function and energy	Sexual function improved modestly, while the primary vitality measure did not [3].	Wellspan	Set expectations by outcome instead of promising a general boost.
Living longer	No randomized trial has shown that TRT extends life. Low natural levels are associated with mortality in observational data [8].	Lifespan	An association does not show that treatment changes lifespan.

TRAVERSE was designed to test cardiovascular safety, not cardiovascular benefit. It enrolled men with symptoms, repeatedly low testosterone, and existing or elevated cardiovascular risk. Major cardiovascular events occurred at similar rates in the testosterone and placebo groups ⁴. The result should not be generalized to unscreened use, supraphysiologic dosing, or men without confirmed deficiency.

In 2025, the FDA removed its boxed warning about increased cardiovascular risk after reviewing TRAVERSE. It retained the limitation on use for age-related decline and added a class-wide warning that testosterone can increase blood pressure ⁹. No trial has established a lifespan benefit. Observational associations between low testosterone and mortality cannot show that TRT prevents death ⁸.

Confirming Testosterone Deficiency: Testing and Retesting

1
Symptoms that fit
Low desire, fewer spontaneous erections, erectile changes, reduced muscle, anemia, or low bone density may support evaluation. Fatigue and low mood are less specific.
2
A repeat morning testosterone
Confirm a low result with a second fasting, early-morning test on a separate day. Symptoms plus consistently low levels are required [1].
3
Free testosterone when it matters
When total testosterone is borderline or SHBG is altered, a reliable free-testosterone estimate or measurement can clarify the result. Direct free-testosterone immunoassays are inaccurate [11].
4
LH and FSH
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) help distinguish a testicular cause from a pituitary or hypothalamic cause.
5
Baseline labs before a prescription
Before starting, check hematocrit, blood pressure, prostate context when appropriate, cardiometabolic risk, sleep apnea, and fertility goals.

Hypogonadism means relevant symptoms or signs together with unequivocally and consistently low morning testosterone ¹. The American Urological Association uses total testosterone below 300 ng/dL as a reasonable diagnostic cutoff ¹⁰. A harmonized reference range in healthy young men placed its lower limit near 264 ng/dL ¹². That reference limit is not a universal treatment threshold.

Results must be interpreted with the laboratory method, symptoms, and clinical context. Poor sleep, obesity, acute illness, heavy alcohol use, some medications, and untreated sleep apnea can affect testosterone or cause similar symptoms. Addressing reversible factors may improve health whether or not TRT is prescribed.

What's the difference between free and total testosterone?

Total testosterone includes free hormone and hormone bound to proteins. Free testosterone is the unbound fraction. It can help when total testosterone is near the lower limit or sex hormone-binding globulin (SHBG) is altered. Use a validated calculation or reliable measurement method rather than a direct immunoassay ¹¹.

Monitoring a TRT Plan

What to watch: Hematocrit
Why it matters: Hematocrit is the percentage of blood volume made up of red blood cells. TRT can raise it and cause erythrocytosis [13].
What triggers a change: A baseline above about 48% warrants evaluation [11]. A level of 54% during treatment calls for a pause or dose reduction [10].

What to watch: Prostate context
Why it matters: PSA is a prostate-related blood marker. In screened trial participants, TRT did not significantly increase high-grade prostate cancer [14]. A broader review found no significant difference in prostate cancer or PSA [15].
What triggers a change: A meaningful PSA rise or exam change can require urology review. The trial excluded men with higher baseline PSA, so its reassurance is not universal.

What to watch: Estradiol
Why it matters: Some testosterone converts to estradiol. Major guidelines do not recommend routine estradiol testing or routine estrogen-blocker use with standard TRT.
What triggers a change: Test when symptoms or a specific clinical question justify it instead of treating a target number routinely.

What to watch: Blood pressure
Why it matters: The FDA added a class-wide warning that testosterone products can increase blood pressure [9].
What triggers a change: Measure blood pressure before treatment and during follow-up. Address a sustained rise.

What to watch: Symptoms and testosterone level
Why it matters: Symptoms show whether treatment is helping. A properly timed testosterone result shows whether exposure is in the intended range.
What triggers a change: Lack of improvement or an out-of-range result should prompt review of the dose, formulation, adherence, or diagnosis.

What to watch: Sleep apnea
Why it matters: The Endocrine Society recommends against starting TRT in untreated severe obstructive sleep apnea (OSA) [1]. Evidence about TRT worsening OSA is limited [16].
What triggers a change: Evaluate and treat suspected severe OSA before starting. Reassess snoring, witnessed pauses, or daytime sleepiness during treatment.

What to watch	Why it matters	What triggers a change
Hematocrit	Hematocrit is the percentage of blood volume made up of red blood cells. TRT can raise it and cause erythrocytosis [13].	A baseline above about 48% warrants evaluation [11]. A level of 54% during treatment calls for a pause or dose reduction [10].
Prostate context	PSA is a prostate-related blood marker. In screened trial participants, TRT did not significantly increase high-grade prostate cancer [14]. A broader review found no significant difference in prostate cancer or PSA [15].	A meaningful PSA rise or exam change can require urology review. The trial excluded men with higher baseline PSA, so its reassurance is not universal.
Estradiol	Some testosterone converts to estradiol. Major guidelines do not recommend routine estradiol testing or routine estrogen-blocker use with standard TRT.	Test when symptoms or a specific clinical question justify it instead of treating a target number routinely.
Blood pressure	The FDA added a class-wide warning that testosterone products can increase blood pressure [9].	Measure blood pressure before treatment and during follow-up. Address a sustained rise.
Symptoms and testosterone level	Symptoms show whether treatment is helping. A properly timed testosterone result shows whether exposure is in the intended range.	Lack of improvement or an out-of-range result should prompt review of the dose, formulation, adherence, or diagnosis.
Sleep apnea	The Endocrine Society recommends against starting TRT in untreated severe obstructive sleep apnea (OSA) [1]. Evidence about TRT worsening OSA is limited [16].	Evaluate and treat suspected severe OSA before starting. Reassess snoring, witnessed pauses, or daytime sleepiness during treatment.

TRT can correct anemia in some men with hypogonadism ¹⁷, yet it can also push hematocrit too high. Monitoring should include the treatment goal, testosterone level, hematocrit, blood pressure, adverse effects, and prostate assessment when appropriate. A DEXA scan is based on bone risk rather than required for every TRT user. The blood-biomarkers guide explains other common tests.

TRT and Fertility

Exogenous testosterone, meaning testosterone taken as medication, suppresses the hormone signals that support sperm production ². Sperm counts can fall substantially or reach zero. Recovery after stopping varies in timing and completeness.

The Endocrine Society recommends against TRT for men planning fertility in the near term ¹. Alternatives such as hCG or clomiphene may be considered under specialist care, depending on the cause of low testosterone ². Discuss semen testing and fertility preservation before starting rather than after a problem appears.

TRT can be stopped with medical guidance, but testosterone levels and symptoms may return toward baseline. Endogenous production and fertility may take time to recover. Starting treatment therefore requires a long-term plan, even though continued use should be reassessed rather than assumed.

Where TRT Fits in a Longevity Plan

TRT can improve specific symptoms in men with confirmed hypogonadism. It should not be treated as a general longevity intervention or prescribed solely to optimize a normal laboratory value. No randomized trial has shown that TRT extends life.

Confirm symptoms and repeat morning levels before treatment. Evaluate reversible causes, discuss fertility, and agree on monitoring. Low testosterone is associated with earlier death in observational data ⁸, but that association does not prove that raising testosterone changes lifespan. Related guides cover thyroid evaluation, menopause hormone therapy, and peptides marketed for growth-hormone support.

Look for a clinician who diagnoses testosterone deficiency according to guidelines, discusses fertility before prescribing, and provides scheduled follow-up. Ask how the service handles high hematocrit, rising blood pressure, lack of symptom improvement, and referrals for prostate or fertility concerns.

The Bottom Line

TRT is supported for men with symptoms and consistently low morning testosterone. Sexual function may improve, while reliable gains in energy, cardiovascular protection, fracture prevention, diabetes prevention, and lifespan have not been shown. A safe plan includes fertility counseling and follow-up for symptoms, testosterone level, hematocrit, blood pressure, sleep apnea, and prostate context. Improvement in a laboratory value is not evidence of a longer life.

References

Bhasin S, Brito JP, Cunningham GR, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism. 2018. JCEM
Crosnoe LE, Grober E, Ohl D, Kim ED. "Exogenous testosterone: a preventable cause of male infertility." Translational Andrology and Urology. 2013. PubMed
Snyder PJ, Bhasin S, Cunningham GR, et al. "Effects of Testosterone Treatment in Older Men." New England Journal of Medicine. 2016. PubMed
Lincoff AM, Bhasin S, Flevaris P, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." New England Journal of Medicine. 2023. PubMed
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. "Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone." JAMA Internal Medicine. 2017. PubMed
Snyder PJ, Bauer DC, Ellenberg SS, et al. "Testosterone Treatment and Fractures in Men with Hypogonadism." New England Journal of Medicine. 2024. PubMed
Bhasin S, Lincoff AM, Nissen SE, et al. "Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism." JAMA Internal Medicine. 2024. PubMed
Yeap BB, et al. "Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men: Individual Participant Data Meta-analyses." Annals of Internal Medicine. 2024. PubMed
U.S. Food and Drug Administration. "FDA issues class-wide labeling changes for testosterone products." 2025. FDA
American Urological Association. "Evaluation and Management of Testosterone Deficiency: AUA Guideline." Journal of Urology. 2018. AUA
VA Pharmacy Benefits Management Services / National Formulary Committee. "Testosterone Replacement Therapy (TRT) in Males: Criteria for Use." 2025. VA
Travison TG, Vesper HW, Orwoll E, et al. "Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies." Journal of Clinical Endocrinology & Metabolism. 2017. JCEM
Cervi A, Balitsky AK. "Testosterone use causing erythrocytosis." Canadian Medical Association Journal. 2017. PMC
Bhasin S, et al. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism." JAMA Network Open. 2023. JAMA Network Open
Xu Z, Chen X, Zhou H, et al. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 2024. Frontiers in Endocrinology
Graziani A, Grande G, Ferlin A. "The complex relation between obstructive sleep apnoea syndrome, hypogonadism and testosterone replacement therapy." Frontiers in Reproductive Health. 2023. PubMed
Pencina KM, Travison TG, Artz AS, et al. "Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism." JAMA Network Open. 2023. PubMed